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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The tertiary structure and domain organization of coagulation factor VIII
Betty W. Shen,1 Paul Clint Spiegel,1 Chong-Hwan Chang,2 Jae-Wook Huh,2 Jung-Sik Lee,2 Jeanman Kim,2 Young-Ho Kim,3
and Barry L. Stoddard1
1Program in Molecular Biophysics, Structure and Design, Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Central Research
Institute, Green Cross Corporation, Yongin, Korea; and 3Department of Life Sciences, The University of Suwon, Kyongi-do, Korea
Factor VIII (fVIII) is a serum protein in the
coagulation cascade that nucleates the
assembly of a membrane-bound protease
complex on the surface of activated plate-
lets at the site of a vascular injury. Hemo-
philia A is caused by a variety of muta-
tions in the factor VIII gene and typically
requires replacement therapy with puri-
fied protein. We have determined the
structure of a fully active, recombinant
form of factor VIII (r-fVIII), which consists
of a heterodimer of peptides, respectively
containing the A1-A2 and A3-C1-C2 do-
mains. The structure permits unambigu-
ous modeling of the relative orientations
of the 5 domains of r-fVIII. Comparison of
the structures of fVIII, fV, and ceruloplas-
min indicates that the location of bound
metal ions and of glycosylation, both of
which are critical for domain stabilization
and association, overlap at some posi-
tions but have diverged at others. (Blood.
2008;111:1240-1247)
© 2008 by The American Society of Hematology
Introduction
The principal mechanism used to stop the loss of blood in mammals
following vascular injury consists of a pair of overlapping proteolytic
cascades called the extrinsic and intrinsic pathways.1-4 The process of
blood coagulation requires extraordinary spatial and temporal regula-
tion, which is accomplished by assembling and tethering the central
proteolytic activities of these cascades at the location of transiently
exposed biomolecules and cellular surfaces (Figure 1A). This includes
an integral membrane protein called “tissue factor” that initiates the
rapid up-regulation of the short-lived extrinsic pathway,5 and the
surfaces of activated platelets, which modulate the activation of the
longer-lived intrinsic pathway.6 A total of 2 homologous procoagulants,
factors V and VIII (fV and fVIII), are each localized on the surface of
these platelets, where they nucleate the assembly of multiprotein
proteolytic complexes.
When fVIII is bound to activated platelets at the site of vascular
injury, it recruits the serine protease fIXa into a complex that then
catalyzes the proteolytic activation of fX.1,4,7 The proteolytic activity of
fIXa is enhanced by approximately 200 000-fold through its interaction
with fVIII, calcium, and the phospholipid bilayer,8 corresponding to an
increase of approximately 109 in kcat/KM.
The full-length, unprocessed fVIII protein consists of 2332
amino acid residues and has the domain structure A1-A2-B-A3-C1-
C29-12 (Figure 1B). The 3 A domains are each approximately
330 residues, and approximately 40% identical to each other and to
the copper-binding protein ceruloplasmin.13 The C domains are
smaller (approximately 160 residues) and are more distantly related
to various members of the discoidin protein fold family, such as
galactose oxidase.14-17 The B domain has no known structural
homologs, is heavily glycosylated, and is relatively dispensible for
procoagulant activity. fVIII is initially processed by proteolytic
cleavage events that remove a large portion of the B domain,
generating a heterodimer that circulates in a tight complex with von
Willebrand factor (VWF).18 This interaction is essential for main-
taining stable levels of fVIII in circulation.19 Upon vascular injury,
further proteolytic processing generates activated factor VIIIa
(fVIIIa), a heterotrimer (A1/A2/A3-C1-C2) that is released from
VWF and binds to activated platelets.18
The carboxy-terminal 159 amino acids of fVIII comprise its C2
domain, which is involved in binding to VWF and primarily
responsible for binding to platelet membrane surfaces. This latter
binding interaction is dependent on the transient, specific exposure
of phosphatidylserine (PS) head groups on the outer leaflet of
activated platelet membranes.20-23 The VWF and membrane-
binding activities of the C2 domain appear to be competitive and
mutually exclusive.23-26
Several structural models are available to the coagulation commu-
nity for analysis of fVIII.Ahypothetical model of the fVIII “A” domains
has been generated from the crystal structure of ceruloplasmin.13 The
structures of the C2 domain of fV and fVIII have been solved to high
resolution,16,27,28 and a homology model of the fVIII C1 domain has
been described.29 Complementing those studies is a model of the
full-length fVIII heterodimer, generated from 2D electron diffraction
studies, which provides a low-resolution (approximately 15 Å) view of
the overall disposition and orientations of the individual fVIII do-
mains.30 Finally, a 2.8-Å resolution structure of a portion of fV (missing
its A2 domain) has also been reported.31
Methods
A recombinant form of fVIII (r-fVIII) was expressed, secreted, and purified
from Chinese hamster ovary (CHO) cells as a heterodimer in the presence
of VWF as previously described.32 The heterodimeric species of r-fVIII
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consists of a heavy chain (A1 and A2 domains) and a light chain (residues
1563-1648 of the B domain and the entire A3, C1, and C2 domains).
Purified r-fVIII was pooled, concentrated to 0.5 mg/mL, and stored at
70°C in storage buffer (50 mM imidazole [pH 6.7]; 410 mM NaCl, 4 mM
CaCl2, 0.1% wt/vol PEG1000, and 0.001% wt/vol Tween 80). This
truncated variant of fVIII maintains procoagulant activity and can be
subsequently activated by thrombin.
For crystallization purposes, r-fVIII was concentrated to 2 mg/mL by
vacuum dialysis at 4°C against the storage buffer listed. r-fVIII was
subsequently crystallized by hanging drop reverse-vapor diffusion at 4°C
against reservoirs containing 8% to 12% (wt/vol) PEG8000, 100 to
300 mM NaCl, and 50 mM Tris-HCl (pH 6.5-7.5). Reverse-vapor diffusion
occurs due to the higher salt concentration residing in the r-fVIII storage
buffer, leading to a reduction in salt concentration in the protein drop that
causes crystallization. Prior to data collection, crystals were cryoprotected
with either 30% (vol/vol) DMSO or 25% to 30% glycerol and flash-frozen
in liquid nitrogen. Data collection was performed at Beamline 5.0.2 at the
Advanced Light Source (Berkeley, CA). Data were indexed, refined, and
integrated with D*TREK (Molecular Structure Corporation, The Wood-
lands, TX)33 and scaled using the program SCALA (CCP4, Daresbury
Laboratory, United Kingdom).34 The space group was determined to be
P41212 by analyses of symmetry and systematic absences, and by examina-
tion of unbiased anomalous difference, isomorphous difference and omit
maps. Particularly obvious validating features of these maps, indicating the
position of bound metals and oligosaccharide structures, are shown in
Figure 2.
The initial crystals used for molecular replacement were cross-linked
(by transient 5-minute exposure to 0.05% vol/vol glutaraldehyde, followed
by cryocooling) and diffracted to approximately 4.5-Å resolution. Subse-
quent crystals were larger, more robust, and diffracted up to approximately
3.7 Å without requiring cross-linking. One of these specimens was used for final
rebuilding and refinement (Tables 1,2). The unit cell parameters for the crystal
used for the final refinement are a  b  134.8 Å and c  358.4 Å.
The phasing of the r-fVIII crystal structure was performed iteratively by
molecular replacement, using the programs Phaser (CCP4) and EPMR.35
First, the 3 A domains of fVIII were simultaneously located and placed with
the program Phaser using a search model consisting of a polyalanine
peptide chain containing those domains, which were derived from the
crystal structure of ceruloplasmin.13 The correct solution to this search was
well above background, with the top 2 Z-scores for the rotation search
corresponding to 7.6 and 3.1, respectively; the top 2 Z-scores for the
translation search were 23.7 and 13.5. A similar search using the coordi-
nates of the A1 and A3 domains from the structure of inactive “A2-deleted”
fV31 was unsuccessful. The position of each of the A domains was further
validated by removing each domain from the solution and performing a
subsequent search to find each domain independently. The position of the
C1 domain was then determined, using a model of C129 derived from the
structure of the fVIII C2 domain16 as a search template. Last, the position of
the C2 domain was determined using the program EPMR with the previous
solutions combined and used as a static structure while the fVIII C2 domain
crystal structure was used as a search model. The resulting solution for the
fVIII C2 domain generated a correlation coefficient of 0.601 and an
R-factor of 50.8.
The relative orientations of the fVIII domains resembles the orienta-
tions of the same domains that were independently determined in the crystal
structure of a fragment of fV.31 That model was not used at any stage of
phase determination in this study. Additional protein models that did not
result in an obvious molecular replacement solution were all-atom cerulo-
plasmin36 and a model derived from electron diffraction data for fVIII.30 In
the latter structure, the orientation of the 2 C domains differ significantly
from those found in the crystal structure reported here.
Homology models of the 3 A domains and the C1 domain were
constructed using the ROBETTA protein structure prediction server.37 The
resulting models were superimposed on the molecular replacement solution
and used as starting models for rigid body refinement using the CNS
program,38 initially for the entire structure as one rigid group, and
subsequently parsed into individual domains as individual rigid groups.
After initial simulated annealing protocols, the values of Rwork and Rfree
were 0.398 and 0.459, respectively, at which point model rebuilding was
commenced against unbiased composite omit maps. During the iterative
process of rebuilding and refinement, sequentially higher quality data sets
were generated as shown in Tables 1,2, and were used accordingly.
Model building was done with the program COOT39 against SIGMAA-
weighted Fourier and difference maps, and the structure was refined using
Figure 1. Factor VIII and the coagulation cascade. (A) The blood coagulation cascade consists of 2 pathways (extrinsic and intrinsic) that are initiated by the exposure of
tissue factor (TF) or phosphatidylserine groups (PS) of activated platelet membranes to circulating protein factors, respectively. fVIII is a plasma glycoprotein that acts as an
initiator and regulator of the intrinsic pathway. Upon proteolytic activation by either fXa or thrombin, fVIIIa dissociates from VWF, associates with the fIXa serine protease, and
directs the localization of the resulting complex to the membrane surface of activated platelets via an interaction with its C-terminal C2 domain (structure in inset). The
membrane-bound complex between fVIIIa and fIXa complex functions to proteolytically activate fX, which then activates thrombin (fII). (B) Domain structure of fVIII. fVIII is
synthesized as a single polypeptide chain of 2332 residues. Based on sequence homology, fVIII has the domain structure A1-A2-B-A3-C1-C2. Linker regions between domains
are denoted with lowercase letters (“a1,” etc). The location of domain boundaries and primary sites of proteolytic processing during secretion and activation are denoted by
residue numbers. The circulating fVIII heterodimer is associated with VWF primarily through interactions with the “a3” acidic region at the light chain N-terminus and with the C2
domain. Various proteases interact with the activated heterotrimer at positions denoted at the bottom panel. Membrane association is primarily accomplished through the C2
domain; its deletion completely abrogates binding of fVIII to platelet surfaces.
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CNS after randomly removing 5% of the measurements to monitor the free
R-factor (Rfree). Due to the low resolution of the X-ray data in this study, all
modifications of the structure during model building and refinement were
evaluated and accepted based on their effect on the value of the Rfree and on
the difference between Rfree and Rwork, rather than solely on the value Rwork
(which is more subject to model bias). During the refinement, features of
unbiased electron density that were correlated with previously unmodeled
structural features (such as the obvious presence of an N-linked, bifurcated
mannose core glycosyl modification of Asn1810, and strong features of
anomalous density for bound metal ions, as shown in Figure 2) provided
clear validation of the molecular replacement solution and subsequent
refinement. The final model corresponds to Rwork/Rfree values of 0.289/0.341
and geometric root mean square deviation (RMSD) values of 0.0092 Å
(bond distance) and 1.69° (bond angles). Data and refinement statistics are
provided in Tables 1 and 2. A comparison of the refinement statistic with
structures at similar resolution in the Protein Databank (PDB) database and
the Ramachandran plot of the current structure are provided in Figures
S1,S2 (available on the Blood website; see the Supplemental Materials link
at the top of the online article).
Results
Structure and domain organization
We crystallized a fully active form of engineered r-fVIII, which
consists of a heterodimer of the A1-A2 domains (the “heavy
chain”) and the A3-C1-C2 domains (the “light chain”). The
structure permits unambiguous modeling of the relative orienta-
tions of all 5 domains of r-fVIII as well as identification of sites of
glycosylation and metal binding (Figure 2). While the C2 domain is
loosely tethered to the structure and appears capable of significant
motion, the C1 domain forms an extensive hydrophobic interface
with the A3 domain and is likely locked into a single docked
position and conformation.
The structures of the individual domains within fVIII are quite
similar to available crystal structures of homologous proteins. The
3 A domains can be superimposed on those from ceruloplasmin13
Figure 2. The structure of the B domain deleted fVIII
heterodimer. (A,B) The fVIII domains are individually
labeled and colored. The C-terminal end of the heavy
chain and the N-terminal end of the light chain are
indicated with residue numbers (715 and 1695). Resi-
dues 1563 to 1694 (the N-terminal 80 residues of the
light chain) are present in the construct but are poorly
ordered. The N- and C-termini of 2 additional disor-
dered regions are also indicated with residue numbers:
residues 220 and 228 that flank a surface loop in the A1
domain (right panel) and residues 334 and 366 that
flank the linker region between the A1 and A2 domains
(left panel). Shown are 2 bound calcium ions, 2 bound
copper ions, and 3 well-ordered and visible N-linked
oligosaccharide structures. Shown and labeled for
reference are 4 residues on the C2 domain that are
thought to be involved in membrane binding and a
similarly positioned pair of residues on the C1 domain.
(C) Anomalous difference peaks at the sites of bound
copper ions buried in the A1 and A3 domains (con-
toured at 5; both are approximately 9 peak height
overall). The residues involved in metal binding at this
site are conserved in the analogous copper-binding site
in ceruloplasmin, but are diverged from fV. (D) Differ-
ence density for 1 of 3 N-linked oligosaccharide struc-
tures, which modifies Asn239 in the A1 domain. The
density is readily apparent for the entire pentameric
polysacharide mannose core of an N-linked sugar, and
represents unbiased density prior to any modeling of
the covalent modification.
Table 1. Data collection and processing statistics
Crystal F8_w (cross-linked) Nat-7 Nat-4b Nat-4c
Wavelength, Å 1.0246 1.00 1.00 1.00
Unit cell, Å a  b  134.7, c  353.6 a  b  134.5, c  359.7 a  b  134.6, c  359.5 a  b  134.8, c  358.4
Resolution, Å 30-4.5 (4.6-4.5) 100-4.3 (4.4-4.3) 100-3.9 (4.0-3.9) 100-3.7 (3.76-3.70)
No. reflections (no. unique reflections) 308 594 (20 241) 133 617 (42 517) 199 559 (28 509) 189 184 (34 208)
Redundancy 15.2 3.1 7.0 (2.9) 5.5 (3.0)
I/ (I)* 19.5 (5.4) 17.7 (3.5) 12.9 (1.0) 13.7 (0.91)
Completeness, %* 100 (100) 97.7 (98.6) 92.5 (61.3) 94.5 (67.3)
Rsym* 0.161 (0.682) 0.084 (0.553) 0.092 (0.735) 0.096 (0.798)
Space group is P41212.
*Numbers in parentheses are statistics from the highest-resolution shells.
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with an overall RMSD of 1.7 Å, and can be similarly superimposed
on the A1 and A3 domains from fV with an RMSD of 2.2 Å. The
C2 domain is closely related to the previously determined crystal
structure of the isolated domain16 (RMSD, 1.5 Å). Comparison of
the 2 individual C domains with those from the crystal structure of
fV gives RMSD values of approximiately1.9 Å.
Across the structure of the fVIII heterodimer, 4 regions are
disordered (Figure 2): 2 short surface loops within the A1 domain
(residues 34-38 and 213-227), the linker region between the A1 and
A2 domains (residues 335-366), and a long 155-residue region
spanning the end of the A2 domain, through the truncated portion
of the B domain, and into the N-terminal region of the A3 domain.
The remaining portion of the light chain (A3-C1-C2) is well
ordered (except for its final 3 residues). The N-terminal residues of
the light chain are critical for binding to VWF and are proteolyti-
cally truncated by thrombin during r-fVIII activation; it is therefore
likely that they are only structurally ordered within the circulating
r-fVIII/vWF complex.
The orientation of the C1 domain is similar to that observed
in the crystal structure of fV31 (which is missing its A2 domain),
but is rotated by approximately 90° relative to the model of
r-fVIII generated from previous 2D electron diffraction studies30
(Figure 3). The C1 domain is tightly associated with the A3
domain of the light chain, creating a 1200-Å2 aromatic/
hydrophobic interface that buries approximately 20 residues and
a well-ordered N-linked high-mannose glycosyl modification of
N2118 (Figure 4A). This interface includes several aromatic
residues (Y1748, Y2017, Y2105, and W2112), 3 prolines
(P1865, P2142 and P2143), several aliphatic residues (L1747,
L1752, V1933, L2015 and I2145), and a large number of
hydrophilic residues, effectively locking the C1 domain into
place within the fVIII light chain. Of the residues in the A3-C1
interface, at least 6 (L1752, N2015, and Y2017 and 2105,
R2116, and T2122) are sites of missense mutations associated
with hemophilia A.
In contrast, the C2 domain is relatively loosely tethered to the
fVIII molecule (Figure 4A), displaying a small 400-Å2 interface to
the C1 domain and a 200-Å2 interface with the A1 domain, both of
which are comprised primarily of hydrophilic residues. However,
the observed orientation of the C2 domain is similar to that
observed in the fV crystal structure, indicating that this domain
orientation is a reproducible feature of the full-length heterodimer
(Figure 3). The respective interactions of the C1 and C2 domains
within the fVIII molecule agree with their observed behavior in
solution when expressed as isolated domains: the C1 domain is
insoluble and cannot readily be purified, while the isolated C2
domain is well behaved in solution at high concentrations and
displays specific binding to both plasma membranes and to
recombinant VWF constructs (behaviors that mimic its role in the
full-length coagulation factor).40,41
Table 2. Model refinement statistics
Resolution, Å 100-3.7 (3.76-3.7)
Rwork 0.289 (0.470)
Rfree 0.341 (0.485)
RMSD bond, Å 0.0092
RMSD angle, ° 1.69
Protein residues/average B-factor, no. 1315/160.1
Carbohydrate moieties/average B-factor, no. 13/192.0
Metal ions/average B-factor, no. 4/158.5
Ramachandran distribution, no. residues (%) 992 (86.9), 107 (9.4), 43 (3.7)
Figure 3. Comparisons of fV and fVIII structures.
The relative domain orientations of r-fVIII with a previ-
ously reported model generated from electron diffrac-
tion studies, and with 2.8-Å resoloution crystal struc-
tures of ceruloplasmin and of an inactive (A2-deleted)
fV construct are shown. The structures are all oriented
similarly with respect to the A domains. Metals ions
modeled in the various structures as calcium and
copper are indicated as yellow and blue spheres,
respectively. The docked orientations of the C domains
of r-fVIII, and their interactions with each other and with
the A3 domain of the light chain, are both rotated by
approximately 90° with respect to the electron diffrac-
tion model, but in excellent agreement with their homolo-
gous domains in fV. The box shows superposition of
full-length fVIII (colored by domains) versus inactive
(A2-deleted) fV (shown in orange). The RMSD for
aligned -carbons is approximately 2 Å.
STRUCTURE OF HUMAN COAGULATION FACTOR VIII 1243BLOOD, 1 FEBRUARY 2008  VOLUME 111, NUMBER 3
For personal use only.on January 29, 2015. by guest  www.bloodjournal.orgFrom 
Bound metal ions and sites of glycosylation
In addition to the protein domains, 4 bound metal ions and 3
sites of glycosylation are observed in the structure (Figure 2).
Acidic residues from individual A domains ligate two of the
metals, which are modeled as calcium ions. The first calcium,
found in the A1 domain, is tightly coordinated by a single
glutamate (E110) and 3 aspartate residues (D116, D125, and
D126), and is located at a position within the protein fold that is
also occupied by calcium in both ceruloplasmin36 and in fV.31
The second modeled calcium is coordinated by 2 aspartate
residues (D538 and D542) in the A2 domain.
The 2 additional metal ions, one each in the A1 and A3 domains,
are observed in anomalous difference Fourier maps (Figure 2C)
and are modeled as copper ions. Previous biochemical studies have
indicated the presence of one or more bound copper ions in these
domains in both human fVIII42 and in fV,43 and a functional role for
bound copper in association of the A1 and A3 domains.44 This
property reflects the relationship of both of these coagulation
factors to the copper-binding protein ceruloplasmin, which con-
tains multiple copper ions bound near the A1-A3 domain interface.
Comparison of these domains among all 3 proteins indicates that
their copper-binding functions are maintained, although with
significant divergence in the identity and position of the side chains
that coordinate the metal ion (Figure S3).
Density for the first bound copper in fVIII is observed in the A3
domain (Figures 2C,S3), coordinated by 2 histidine residues
(H1954 and H2005) and a single cysteine (C2000). This metal
binding site is conserved in ceruloplasmin, which is occupied by a
similarly located copper ion.36 In fV, a single bound copper ion is
also located near the A1-A3 boundary, again coordinated entirely
by residues from the A3 domain (H1802, H1804, and D1844).
These amino acid ligands differ from fVIII, but are also partially
conserved with ceruloplasmin.
A second bound copper ion is buried in the A1 domain of
fVIII, and is also coordinated by 2 histidine residues (H267 and
H315) and a single cysteine (C310; Figure 2C). The metal-
binding residues in this site are again conserved in ceruloplas-
min, but not in fV (where the corresponding residues are F239,
H207, and S282).
Overall, the metal-binding function of fVIII appears to be more
closely related to ceruloplasmin than to fV. fV and fVIII each share
homology in copper-binding residues with ceruloplasmin, but not
with each other; this may indicate that the 2 coagulation factors
have independently diverged from a common copper-binding
ancestor. It is possible that additional or alternate copper binding
sites may be occupied in various fVIII and/or fV constructs,
depending on the precise nature of the expression system and cell
line. The encorporation of copper ions in proteins, unlike transition
metals such as calcium and magnesium, is known to often require
Figure 4. Interface dimensions and packing in the
r-fVIII molecule. (A) The light chain and packing of the
C domains. The C1 domain (cyan ribbon and pink side
chains) is engaged in an extensive docked interaction
against the A3 domain (light magenta ribbon and yellow
side chains) that involves multiple aromatic, aliphatic,
and hydrophilic side chains, several of which are sites
of missense mutations associated with protein dysfunc-
tion and hemophilia A. An N-linked glycosyl modifica-
tion (red) is also involved in the C1-A3 interface. In
contrast, the C2 domain (blue ribbon and side chains)
is loosely tethered to the r-fVIII molecule, displaying
small, entirely hydrophilic interfaces with the A3 and C1
domains. Interestingly, a number of residues in these
interfaces are also associated with hemophilia.
(B) Packing of the trimer of A domains and close up of
the packing of the A2 domain (green) against the
A3 domain, with residues that have been previously
mutated to create engineered disulfide cross-links indi-
cated. These residues are located on 2 adjacent loops
in the A domains, which appear to display sufficient
flexibility to permit covalent disulfide formation while
maintaining r-fVIII activity in vivo.
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specific chaperones that are highly specific to individual protein
targets and expression pathways.
Of 4 potential sites of N-linked glycosylation in the r-fVIII
molecule (N42 and N239 in the A1 domain, N1810 in the A3
domain, and N2118 in the C1 domain), density is clearly visible for
an oligosaccharide structure consistent with a canonical N-linked
modification at N239, N1810, and N2118. One of these 3 positions
(N1810) is also observed to be glycosylated in the structure of fV.31
Of the glycosylation modifications in fVIII, unbiased difference
density is particularly striking for extensive well-ordered oligosac-
charide structures at both N239 (Figure 2D) and N2118. In both
cases, the sugar moieties are located in a domain interface (between
A1 and A2 for N239, and between A3 and C1 for N2118) and
appear to participate in packing and stabilization. In contrast, the
oligosaccharide group at N1810 is located near a surface of the A3
domain that is believed to be involved in binding both VWF
(through interactions with its N-terminal acidic region) and with
LDL receptors involved in fVIII clearance.45 Thus, this latter
modification, if physiologically relevant, may be important for
stabilization and/or clearance of fVIII in vivo.
Discussion
Hemophilia A mutations
A deficiency in fVIII clotting activity leads to a common bleeding
disorder, hemophilia A, which affects 1 in 5000 males worldwide.46
Hemophilia A is an X-linked disorder of variable severity that is
due to mutations in the fVIII gene, which is 187 kb long and
contains 26 exons. The genetic lesions resulting in hemophilia A
include deletions, exon inversions and translocations, nonsense
frame shifts, premature stops, and a large number of missense point
mutations, all of which can cause defects in the expression,
secretion, and/or half-life of fVIII in circulation.47 Alternatively,
some hemophilic mutations can generate stable but dysfunctional
fVIII. An international database of point mutations that are
associated with hemophilia A lists several hundred unique missense
mutations within fVIII that all have been observed in vivo and are
associated with variable severity of disease symptoms.48 These
mutations are distributed uniformly across the entire peptide chain
of fVIII, regardless of either disease severity or structural domain
of the protein (Figure 5A).
A variety of studies have mapped hemophilia A mutations to
positions across available models of the fVIII structure. For
example, upon determination of the crystal structure of the C2
domain and generation of a related homology model of the C1
domain, 57 separate mutations that occur within those regions were
analyzed with respect to the correlation between disease severity,
effect on circulating levels of r-fVIII, and the position of each
residue in the protein fold.29 As a general rule, those residues found
in core regions of these folded domains, or among surface epitopes
known to be critical for procoagulant-binding activities and
functions, were more likely to yield dysfunctional and/or destabi-
lized protein. The structure of the full-length r-fVIII protein
provides additional detail for these analyses, particularly for
mutations located within interfaces between the C domains and
their nearest neighbors in the full-length molecule. For example,
9 separate mutations that yield severe disease symptoms and
phenotypes (defined as those that produce less than 1% of normal
circulating fVIII activity) are found on the surface of the A1, C1,
and C2 domains at positions not known to be involved in binding
interactions with membranes, VWF, or fIXa. These residues are
found to be located, respectively, in the C1-A3 domain interface
(R2116 and T2122), in the A1-C2 interface (T118, E122, and
D116) and in the C1-C2 interface (G2026, G2179, G2325, and
I2032; Figure 5B). These latter residues are of particular interest, as
glycine residues are often of great structural importance for
formation of functional protein cores and interfaces due to their
ability to assume backbone conformations that are otherwise
sterically inaccessible.
Engineered fVIII constructs
Hemophilia A is treated by replacement therapy with concentrated
fVIII using typical dosage regiments of 20 to 40 IU/kg 3 times per
week, plus prophylactic administration during adverse bleeding
episodes.49 A major issue that greatly affects replacement therapy
efficacy and cost is the instability and rapid clearance of fVIII.
Upon activation, the resulting activated fVIIIa is subject to
spontaneous decay of its procoagulant activity, attributable to
first-order dissociation of its free A2 subunit.50 In addition, the
Figure 5. Location of hemophilia A–associated
missense mutations across the r-fVIII structure.
(A) The disease phenotype/symptom designations of
“mild,” “moderate,” and “severe” are taken from the
HamSters database48 and correspond to plasma fVIIIa
activity levels of 6% to 30%, 1% to 5% and less than
1%, respectively. (B) The presence of mutations in the
interfaces of the C domains with each other and with
the A3 domain.
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fVIIIa molecule is cleared by receptor-mediated catabolism, which
is mediated by interactions between well-mapped epitopes on the
surface of fVIII and 2 receptors from the low-density lipoprotein
family (LRP and LDLR; reviewed in Saenko and Pipe49). Many
investigators have hypothesized that improvement of fVIII stability
may allow correction of hemostasis in vivo at lower levels of
protein, allowing for longer intervals between therapeutic infusions.
A variety of strategies have been tested for stabilization of fVIII
and improvement of its circulating lifetime in replacement therapy.49
Specifically, fVIII has been altered by chemical modification
(primarily via “PEGylated” protein formulations), by elimination
of the B domain and additional protein modifications that co-
valently trap the A2 domain (either by elimination of a thrombin-
processing site in the fVIII backbone or by introduction of disulfide
bonds between A2 and A3 domains), and finally by mutagenesis of
proposed receptor-binding residues. The structure of r-fVIII pro-
vides insight into the design of engineered fVIII variants, particu-
larly with respect to disulfide cross-linked constructs (Figure 4B).
Two such constructs have previously been described in some detail:
the first containing a pair of cysteines linking residue 664 of the A2
domain to residue 1826 of the A3 domain (Y664C/T1826C), and
the second, located in the same region, linking residues 662 and
1828 (M662C/D1828C).51 In the crystal structure, these residues
pairs are positioned within 2 adjacent loops and display appropriate
distances for S-S formation (distance between C-alphas is approxi-
mately 7 Å and 13 Å, respectively). The use of structural
information may be of utility for the creation of new generations of
improved fVIII constructs, including those that are stabilized
through resculpting the A2 interface solely through increased
complementarity of noncovalent contacts and packing using struc-
ture-based computational protein design methods.
Antibody inhibitor epitopes
A significant complication of fVIII replacement therapy is the
development of antibody inhibitors.52 The most frequent inhibitor
incidence occurs on epitopes within the A2 and C2 domains.
Inhibitors to the A3 domain and the acidic region between A1 and
A2 have also been observed. fVIII antibody inhibitors can block
fVIII function in several ways: (1) by blocking the ability of fVIIIa
to bind and activate fIXa and fX; (2) by inhibiting the binding of
fVIII to VWF and/or negatively charged phospholipid surfaces; or
(3) by hindering the activation of fVIII by thrombin (and/or fXa) or
the subsequent release of fVIII from VWF.
The antigenic hotspots identified across the surface of r-fVIII
generally correspond to the most mobile regions of the r-fVIII
structure (Figure S4). A total of 2 epitopes (residues 351-365 in the
A1 domain and residues 1674-1684 in the A3 domain) are
disordered in the crystal, while another 2 (residues 484-508 in the
A2 domain and residues 1814-1819 in the A3 domain) correspond
to some of the most elevated B-factors in the structure. In contrast,
the C2 domain, of which at least half has been implicated in
inhibitor antibody binding, is internally well ordered; however, the
domain as a whole is extensively solvent-exposed and only loosely
docked to the remainder of the r-fVIII molecule. The importance of
this domain in several critical procoagulant functions may make
the existence of corresponding inhibitors particularly significant
clinically, facilitating their identification and characterization.
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